MEDICAL
Neurent Medical announces publication of positive randomised controlled trial
results for the NEUROMARK System Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, this year announced the publication of positive results from its randomised controlled trial (RCT) evaluating the NEUROMARK System in the International Forum of Allergy & Rhinology
T
he study demonstrated that treatment with the NEUROMARK System, an impedance controlled radiofrequency
ablation device indicated for chronic rhinitis, is superior to sham control in improving nasal symptoms and quality-of-life measures. The prospective, multicenter, single-blind,
superiority RCT randomised 132 participants to either active treatment with the NEUROMARK System or a sham control. The primary endpoint Nasal Symptom Score (rTNSS) responder rate between treatment arms at 90 days. Secondary cough, Nasal Obstruction Symptom Evaluation (NOSE), mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ) and Patient Health Questionnaire-9 (PHQ-9).
• higher in the active treatment arm (73.3 per cent) compared to the sham control arm (35.0 per cent) (p < 0.001), meeting the primary endpoint and demonstrating superiority of the NEUROMARK System. • Participants treated with NEUROMARK
26 March/April 2026 Irish Manufacturing
improvements in rTNSS, postnasal drip, chronic cough, NOSE score, mini-RQLQ and PHQ-9 compared to sham control.
• NOSE and mini-RQLQ responder rates treatment arm than in the sham control arm. “These results provide high-level clinical evidence supporting posterior nasal nerve ablation with impedance controlled radiofrequency energy as an effective treatment option for patients suffering from chronic rhinitis,” says Mas Takashima, MD, Principal Investigator of the trial and lead author of the publication. both symptom-based and quality-of-life measures highlight the meaningful impact this therapy can have for patients whose symptoms persist despite medical management.” Neurent Medical, added, “The publication of this randomised controlled trial represents another major milestone for Neurent and reinforces our commitment to evidence-based innovation. Demonstrating superiority versus sham in a rigorous RCT underscores the clinical value of
the NEUROMARK System and strengthens the foundation for broader adoption of posterior nasal nerve ablation in the treatment of chronic rhinitis.”
The NEUROMARK System is designed
to deliver multipoint impedance controlled radiofrequency energy to the posterior nasal nerve region, targeting the underlying neural drivers of chronic rhinitis symptoms. Results from this study further support its role as a minimally invasive treatment option for appropriate patients.
ABOUT NEURENT MEDICAL Neurent Medical is a medical device company dedicated to developing innovative, non-surgical solutions for patients suffering from chronic rhinitis. The company’s NEUROMARK System leverages radiofrequency technology to address the underlying neural pathways contributing to chronic nasal symptoms. Neurent Medical is headquartered in Galway, Ireland.
https://neuromark.com/
www.irish-manufacturing.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
